Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
23
self-reported 11–50 band
Founded
2016
10 years
Legal entities
1
ACRA
Office countries
2
2 addresses
Funding rounds
5
Grant · Oct 2024 · US$ 250.0K
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
IMMUNOSCAPE PTE. LTD.Entity record →
UEN201633363C
Legal entities
Show as table · ImmunoScape: 1 registry entity
| IMMUNOSCAPE PTE. LTD. | UEN 201633363C |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.
To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
Specialties
All 13 specialties
- immunotherapy
- mass cytometry
- immunomonitoring
- T cell antigens
- oncology
- infectious diseases
- autoimmune diseases
- cytographer
- Immunoprofiling
- CyTOF
- neoantigen
- biomarker
- vaccine
Locations
2
Countries with an office address2 addresses on record
SingaporeprimaryUnited States
Country footprint
Show as table · Offices in 2 countries
| Countries | 2 |
|---|---|
| Primary country | SG |
All codes: SG US
Addresses
- SG1 Scotts Road; SingaporePrimary
- USOne Broadway; Cambridge, MA 02142
Grid intelligence Members
Funding
Rounds5
Round typeGrant · non-equity funding
Amount (USD)250,000
Stage rank1
Investors named1
Since last round1 yr 3 mo
Funding
Show as table · 5 funding rounds
| Rounds | 5 |
|---|---|
| Axis | 2016 to 2026 |
| Grant · 18 Oct 2024 | US$ 250.0K |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under ImmunoScape?
One Singapore entity on ACRA: IMMUNOSCAPE PTE. LTD. (UEN 201633363C), high confidence.
How many people work at ImmunoScape?
23 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does ImmunoScape have offices?
Two addresses on record across 2 countries. Primary: 1 Scotts Road, Singapore.
Has ImmunoScape raised funding?
Five rounds. Latest 18 October 2024: grant, US$250,000, investor ScaleReady.
What does ImmunoScape list as its specialties?
13 tags on the brand's own list, among them oncology and infectious diseases.
Which companies are listed alongside ImmunoScape?
10 profiles list ImmunoScape as a peer — 82nd percentile in Biotechnology Research. It lists ten peers of its own. Engine Biosciences and Tikva Allocell Pte Ltd list it back.